Skip to main content
Erschienen in: Current Breast Cancer Reports 2/2015

01.06.2015 | Risk, Prevention, and Screening (TA Patel, Section Editor)

Current Multidisciplinary Management of High-Risk Breast Lesions

verfasst von: Therese B. Bevers, Isabelle Bedrosian, Lavinia P. Middleton, Marion E. Scoggins

Erschienen in: Current Breast Cancer Reports | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

For years, surgical excision has been the standard of care for women with proliferative lesions such as atypical hyperplasia or lobular carcinoma in situ identified on needle biopsy because of concern of co-existing occult cancer. However, emerging evidence has suggested a more personalized approach of identifying women for whom surgical excision may be appropriate. A number of variables have been shown to be associated with an increased risk of a pathologic upgrade; this affords the opportunity for selective surgical excision. All women with these proliferative lesions, whether diagnosed on needle biopsy or surgical excision, are at increased risk of future breast cancers and derive significant risk reduction with endocrine therapy. Unless contraindicated, all women with atypical hyperplasia and lobular carcinoma in situ should be started on preventive therapy.
Literatur
2.
Zurück zum Zitat McLaughlin CT, Neal CH, Helvie MA. Is the upgrade rate of atypical ductal hyperplasia diagnosed by core needle biopsy of calcifications different for digital and film-screen mammography? AJR Am J Roentgenol. 2014;203(4):917–22. doi:10.2214/AJR.13.11862.CrossRefPubMed McLaughlin CT, Neal CH, Helvie MA. Is the upgrade rate of atypical ductal hyperplasia diagnosed by core needle biopsy of calcifications different for digital and film-screen mammography? AJR Am J Roentgenol. 2014;203(4):917–22. doi:10.​2214/​AJR.​13.​11862.CrossRefPubMed
3.
Zurück zum Zitat Kim HS, Han BK, Choo KS, Jeon YH, Kim JH, Choe YH. Screen-film mammography and soft-copy full-field digital mammography: comparison in the patients with microcalcifications. Kor J Radiol : Off J Kor Radiol Soc. 2005;6(4):214–20.CrossRef Kim HS, Han BK, Choo KS, Jeon YH, Kim JH, Choe YH. Screen-film mammography and soft-copy full-field digital mammography: comparison in the patients with microcalcifications. Kor J Radiol : Off J Kor Radiol Soc. 2005;6(4):214–20.CrossRef
4.
Zurück zum Zitat Del Turco MR, Mantellini P, Ciatto S, Bonardi R, Martinelli F, Lazzari B, et al. Full-field digital versus screen-film mammography: comparative accuracy in concurrent screening cohorts. AJR Am J Roentgenol. 2007;189(4):860–6. doi:10.2214/AJR.07.2303.CrossRefPubMed Del Turco MR, Mantellini P, Ciatto S, Bonardi R, Martinelli F, Lazzari B, et al. Full-field digital versus screen-film mammography: comparative accuracy in concurrent screening cohorts. AJR Am J Roentgenol. 2007;189(4):860–6. doi:10.​2214/​AJR.​07.​2303.CrossRefPubMed
5.
Zurück zum Zitat Weigel S, Decker T, Korsching E, Hungermann D, Bocker W, Heindel W. Calcifications in digital mammographic screening: improvement of early detection of invasive breast cancers? Radiology. 2010;255(3):738–45. doi:10.1148/radiol.10091173.CrossRefPubMed Weigel S, Decker T, Korsching E, Hungermann D, Bocker W, Heindel W. Calcifications in digital mammographic screening: improvement of early detection of invasive breast cancers? Radiology. 2010;255(3):738–45. doi:10.​1148/​radiol.​10091173.CrossRefPubMed
6.
Zurück zum Zitat Neal CH, Coletti MC, Joe A, Jeffries DO, Helvie MA. Does digital mammography increase detection of high-risk breast lesions presenting as calcifications? AJR Am J Roentgen. 2013;201(5):1148–54. doi:10.2214/AJR.12.10195.CrossRef Neal CH, Coletti MC, Joe A, Jeffries DO, Helvie MA. Does digital mammography increase detection of high-risk breast lesions presenting as calcifications? AJR Am J Roentgen. 2013;201(5):1148–54. doi:10.​2214/​AJR.​12.​10195.CrossRef
8.
Zurück zum Zitat Eby PR, Ochsner JE, DeMartini WB, Allison KH, Peacock S, Lehman CD. Frequency and upgrade rates of atypical ductal hyperplasia diagnosed at stereotactic vacuum-assisted breast biopsy: 9-versus 11-gauge. AJR Am J Roentgenol. 2009;192(1):229–34. doi:10.2214/AJR.08.1342.CrossRefPubMed Eby PR, Ochsner JE, DeMartini WB, Allison KH, Peacock S, Lehman CD. Frequency and upgrade rates of atypical ductal hyperplasia diagnosed at stereotactic vacuum-assisted breast biopsy: 9-versus 11-gauge. AJR Am J Roentgenol. 2009;192(1):229–34. doi:10.​2214/​AJR.​08.​1342.CrossRefPubMed
9.
Zurück zum Zitat Hong ZJ, Chu CH, Fan HL, Hsu HM, Chen CJ, Chan DC, et al. Factors predictive of breast cancer in open biopsy in cases with atypical ductal hyperplasia diagnosed by ultrasound-guided core needle biopsy. Eur J Surg Oncol : J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2011;37(9):758–64. doi:10.1016/j.ejso.2011.06.014.CrossRef Hong ZJ, Chu CH, Fan HL, Hsu HM, Chen CJ, Chan DC, et al. Factors predictive of breast cancer in open biopsy in cases with atypical ductal hyperplasia diagnosed by ultrasound-guided core needle biopsy. Eur J Surg Oncol : J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2011;37(9):758–64. doi:10.​1016/​j.​ejso.​2011.​06.​014.CrossRef
10.
Zurück zum Zitat Jang M, Cho N, Moon WK, Park JS, Seong MH, Park IA. Underestimation of atypical ductal hyperplasia at sonographically guided core biopsy of the breast. AJR Am J Roentgenol. 2008;191(5):1347–51. doi:10.2214/ajr.07.3643.CrossRefPubMed Jang M, Cho N, Moon WK, Park JS, Seong MH, Park IA. Underestimation of atypical ductal hyperplasia at sonographically guided core biopsy of the breast. AJR Am J Roentgenol. 2008;191(5):1347–51. doi:10.​2214/​ajr.​07.​3643.CrossRefPubMed
11.
12.
Zurück zum Zitat Mesurolle B, Perez JC, Azzumea F, Lemercier E, Xie X, Aldis A, et al. Atypical ductal hyperplasia diagnosed at sonographically guided core needle biopsy: frequency, final surgical outcome, and factors associated with underestimation. AJR Am J Roentgenol. 2014;202(6):1389–94. doi:10.2214/AJR.13.10864.CrossRefPubMed Mesurolle B, Perez JC, Azzumea F, Lemercier E, Xie X, Aldis A, et al. Atypical ductal hyperplasia diagnosed at sonographically guided core needle biopsy: frequency, final surgical outcome, and factors associated with underestimation. AJR Am J Roentgenol. 2014;202(6):1389–94. doi:10.​2214/​AJR.​13.​10864.CrossRefPubMed
13.
Zurück zum Zitat Liberman L, Holland AE, Marjan D, Murray MP, Bartella L, Morris EA, et al. Underestimation of atypical ductal hyperplasia at MRI-guided 9-gauge vacuum-assisted breast biopsy. AJR Am J Roentgenol. 2007;188(3):684–90. doi:10.2214/ajr.06.0809.CrossRefPubMed Liberman L, Holland AE, Marjan D, Murray MP, Bartella L, Morris EA, et al. Underestimation of atypical ductal hyperplasia at MRI-guided 9-gauge vacuum-assisted breast biopsy. AJR Am J Roentgenol. 2007;188(3):684–90. doi:10.​2214/​ajr.​06.​0809.CrossRefPubMed
14.
Zurück zum Zitat Strigel RM, Eby PR, Demartini WB, Gutierrez RL, Allison KH, Peacock S, et al. Frequency, upgrade rates, and characteristics of high-risk lesions initially identified with breast MRI. AJR Am J Roentgenol. 2010;195(3):792–8.CrossRefPubMed Strigel RM, Eby PR, Demartini WB, Gutierrez RL, Allison KH, Peacock S, et al. Frequency, upgrade rates, and characteristics of high-risk lesions initially identified with breast MRI. AJR Am J Roentgenol. 2010;195(3):792–8.CrossRefPubMed
16.
17.
20.
Zurück zum Zitat Dmytrasz K, Tartter PI, Mizrachy H, Chinitz L, Rosenbaum Smith S, Estabrook A. The significance of atypical lobular hyperplasia at percutaneous breast biopsy. Breast J. 2003;9(1):10–2.CrossRefPubMed Dmytrasz K, Tartter PI, Mizrachy H, Chinitz L, Rosenbaum Smith S, Estabrook A. The significance of atypical lobular hyperplasia at percutaneous breast biopsy. Breast J. 2003;9(1):10–2.CrossRefPubMed
21.
Zurück zum Zitat Shah-Khan MG, Geiger XJ, Reynolds C, Jakub JW, Deperi ER, Glazebrook KN. Long-term follow-up of lobular neoplasia (atypical lobular hyperplasia/lobular carcinoma in situ) diagnosed on core needle biopsy. Ann Surg Oncol. 2012;19(10):3131–8. doi:10.1245/s10434-012-2534-9.CrossRefPubMed Shah-Khan MG, Geiger XJ, Reynolds C, Jakub JW, Deperi ER, Glazebrook KN. Long-term follow-up of lobular neoplasia (atypical lobular hyperplasia/lobular carcinoma in situ) diagnosed on core needle biopsy. Ann Surg Oncol. 2012;19(10):3131–8. doi:10.​1245/​s10434-012-2534-9.CrossRefPubMed
23.
Zurück zum Zitat Tavassoli Pathology and Genetics of Tumors of the Breast and Female Organs. P. Devilee and F. A. Tavassoli, Eds., Lyon, France: IARC Press; 2003. Tavassoli Pathology and Genetics of Tumors of the Breast and Female Organs. P. Devilee and F. A. Tavassoli, Eds., Lyon, France: IARC Press; 2003.
24.
Zurück zum Zitat Jackman RJ, Birdwell RL, Ikeda DM. Atypical ductal hyperplasia: can some lesions be defined as probably benign after stereotactic 11-gauge vacuum- assisted biopsy, eliminating the recommendation for surgical excision? Radiology. 2002;224(2):548–54.CrossRefPubMed Jackman RJ, Birdwell RL, Ikeda DM. Atypical ductal hyperplasia: can some lesions be defined as probably benign after stereotactic 11-gauge vacuum- assisted biopsy, eliminating the recommendation for surgical excision? Radiology. 2002;224(2):548–54.CrossRefPubMed
25.
Zurück zum Zitat Winchester DJ, Bernstein JR, Jeske JM, et al. Upstaging of atypical ductal hyper-plasia after vacuum-assisted 11-gauge stereotactic core needle biopsy. Arch Surg. 2003;138(6):619–22. discussion: 622–3.CrossRefPubMed Winchester DJ, Bernstein JR, Jeske JM, et al. Upstaging of atypical ductal hyper-plasia after vacuum-assisted 11-gauge stereotactic core needle biopsy. Arch Surg. 2003;138(6):619–22. discussion: 622–3.CrossRefPubMed
26.
Zurück zum Zitat Sohn V, Arthurs Z, Herbert G, et al. Atypical ductal hyperplasia: improved accuracy with the 11-gauge vacuum-assisted versus the 14-gauge core biopsy needle. Ann Surg Oncol. 2007;14(9):2497–501.CrossRefPubMed Sohn V, Arthurs Z, Herbert G, et al. Atypical ductal hyperplasia: improved accuracy with the 11-gauge vacuum-assisted versus the 14-gauge core biopsy needle. Ann Surg Oncol. 2007;14(9):2497–501.CrossRefPubMed
27.
Zurück zum Zitat Deshaies I, Provencher L, Jacob S, et al. Factors associated with upgrading to malignancy at surgery of atypical ductal hyperplasia diagnosed on core biopsy. Breast. 2011;20(1):50–5.CrossRefPubMed Deshaies I, Provencher L, Jacob S, et al. Factors associated with upgrading to malignancy at surgery of atypical ductal hyperplasia diagnosed on core biopsy. Breast. 2011;20(1):50–5.CrossRefPubMed
28.
Zurück zum Zitat Burak Jr WE, Owens KE, Tighe MB, et al. Vacuum-assisted stereotactic breast biopsy: histologic underestimation of malignant lesions. Arch Surg. 2000;135(6):700–3.CrossRefPubMed Burak Jr WE, Owens KE, Tighe MB, et al. Vacuum-assisted stereotactic breast biopsy: histologic underestimation of malignant lesions. Arch Surg. 2000;135(6):700–3.CrossRefPubMed
29.
Zurück zum Zitat Green S, Khalkhali I, Azizollahi E, et al. Excisional biopsy of borderline lesions after large bore vacuum-assisted core needle biopsy—is it necessary? Am Surg. 2011;77(10):1358–60.PubMed Green S, Khalkhali I, Azizollahi E, et al. Excisional biopsy of borderline lesions after large bore vacuum-assisted core needle biopsy—is it necessary? Am Surg. 2011;77(10):1358–60.PubMed
30.
Zurück zum Zitat Fraser JL, Raza S, Chorny K, Connolly JL, Schnitt SJ. Columnar alteration with prominent apical snouts and secretions: a spectrum of changes frequently present in breast biopsies performed for microcalcifications. Am J Surg Pathol. 1998;22(12):1521–7.CrossRefPubMed Fraser JL, Raza S, Chorny K, Connolly JL, Schnitt SJ. Columnar alteration with prominent apical snouts and secretions: a spectrum of changes frequently present in breast biopsies performed for microcalcifications. Am J Surg Pathol. 1998;22(12):1521–7.CrossRefPubMed
32.
Zurück zum Zitat Rosen PP. Columnar cell hyperplasia is associated with lobular carcinoma in situ and tubular carcinoma. Am J Surg Pathol. 1999;23(12):1561.CrossRefPubMed Rosen PP. Columnar cell hyperplasia is associated with lobular carcinoma in situ and tubular carcinoma. Am J Surg Pathol. 1999;23(12):1561.CrossRefPubMed
33.
Zurück zum Zitat Boulos FI, Dupont WD, Simpson JF, Schuyler PA, Sanders ME, Freudenthal ME, et al. Histologic associations and long-term cancer risk in columnar cell lesions of the breast: a retrospective cohort and a nested case–control study. Cancer. 2008;113(9):2415–21. doi:10.1002/cncr.23873.CrossRefPubMedCentralPubMed Boulos FI, Dupont WD, Simpson JF, Schuyler PA, Sanders ME, Freudenthal ME, et al. Histologic associations and long-term cancer risk in columnar cell lesions of the breast: a retrospective cohort and a nested case–control study. Cancer. 2008;113(9):2415–21. doi:10.​1002/​cncr.​23873.CrossRefPubMedCentralPubMed
34.
Zurück zum Zitat Calhoun BC, Sobel A, White RL, Gromet M, Flippo T, Sarantou T, et al. Management of flat epithelial atypia on breast core biopsy may be individualized based on correlation with imaging studies. Mod Pathol. 2014. doi:10.1038/modpathol.2014.159.PubMed Calhoun BC, Sobel A, White RL, Gromet M, Flippo T, Sarantou T, et al. Management of flat epithelial atypia on breast core biopsy may be individualized based on correlation with imaging studies. Mod Pathol. 2014. doi:10.​1038/​modpathol.​2014.​159.PubMed
35.
Zurück zum Zitat Gomes DS, Balabram D, Porto SS, Gobb H. Lobular neoplasia: frequency and association with other breast lesions. Diagnostic Pathol. 2011;6:74. doi:10.1097/PAS.CrossRef Gomes DS, Balabram D, Porto SS, Gobb H. Lobular neoplasia: frequency and association with other breast lesions. Diagnostic Pathol. 2011;6:74. doi:10.​1097/​PAS.CrossRef
36.
Zurück zum Zitat Haagensen CD, Lane N, Lattes R, Bodian C. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer. 1978;42(2):737–69.CrossRefPubMed Haagensen CD, Lane N, Lattes R, Bodian C. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer. 1978;42(2):737–69.CrossRefPubMed
37.
Zurück zum Zitat Page DL, Kidd Jr TE, Dupont WD, Simpson JF, Rogers LW. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol. 1991;22(12):1232–9.CrossRefPubMed Page DL, Kidd Jr TE, Dupont WD, Simpson JF, Rogers LW. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol. 1991;22(12):1232–9.CrossRefPubMed
38.
Zurück zum Zitat Abdel-Fatah TM, Powe DG, Hodi Z, Lee AH, Reis-Filho JS, Ellis IO. High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol. 2007;31(3):417–26.CrossRefPubMed Abdel-Fatah TM, Powe DG, Hodi Z, Lee AH, Reis-Filho JS, Ellis IO. High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol. 2007;31(3):417–26.CrossRefPubMed
39.
Zurück zum Zitat Page DL, Anderson TJ, Rogers LN. Lobular carcinoma in situ. In: Page DL, Anderson TJ, editors. Diagnostic histopathology of the breast. New York: Churchill Livingston; 1987. p. 174–82. Page DL, Anderson TJ, Rogers LN. Lobular carcinoma in situ. In: Page DL, Anderson TJ, editors. Diagnostic histopathology of the breast. New York: Churchill Livingston; 1987. p. 174–82.
40.
Zurück zum Zitat Dabbs DJ, Schnitt SJ, Geyer FC, Weigelt B, Baehner FL, Decker T, et al. Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am J Surg Pathol. 2013;37(7):e1–11.CrossRefPubMed Dabbs DJ, Schnitt SJ, Geyer FC, Weigelt B, Baehner FL, Decker T, et al. Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am J Surg Pathol. 2013;37(7):e1–11.CrossRefPubMed
41.
Zurück zum Zitat Nordgard SH, Johansen FE, Alnaes GI, Bucher E, Syvänen AC, Naume B, et al. Genome-wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients. Genes Chromosomes Cancer. 2008;47(8):680–96. doi:10.1002/gcc.20569.CrossRefPubMed Nordgard SH, Johansen FE, Alnaes GI, Bucher E, Syvänen AC, Naume B, et al. Genome-wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients. Genes Chromosomes Cancer. 2008;47(8):680–96. doi:10.​1002/​gcc.​20569.CrossRefPubMed
42.
Zurück zum Zitat Lakhani SR, Collins N, Stratton MR, Sloane JP. Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. J Clin Pathol. 1995;48(7):611–5.CrossRefPubMedCentralPubMed Lakhani SR, Collins N, Stratton MR, Sloane JP. Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. J Clin Pathol. 1995;48(7):611–5.CrossRefPubMedCentralPubMed
43.
Zurück zum Zitat Buckley ES, Webster F, Hiller JE, Roder DM, Farshid G. A systematic review of surgical biopsy for LCIS found at core needle biopsy - do we have the answer yet? Eur J Surg Oncol. 2014;40:168.CrossRefPubMed Buckley ES, Webster F, Hiller JE, Roder DM, Farshid G. A systematic review of surgical biopsy for LCIS found at core needle biopsy - do we have the answer yet? Eur J Surg Oncol. 2014;40:168.CrossRefPubMed
44.••
Zurück zum Zitat Middleton LP et al. Most lobular carcinoma in situ and atypical lobular hyperplasia diagnosed on core needle biopsy can be managed clinically with radiologic follow-up in a multidisciplinary setting. Cancer Med. 2014;3:492. This single institution analysis identifies variables that distinguish which women with lobular neoplasia may be observed versus those requiring surgical excision.CrossRefPubMedCentralPubMed Middleton LP et al. Most lobular carcinoma in situ and atypical lobular hyperplasia diagnosed on core needle biopsy can be managed clinically with radiologic follow-up in a multidisciplinary setting. Cancer Med. 2014;3:492. This single institution analysis identifies variables that distinguish which women with lobular neoplasia may be observed versus those requiring surgical excision.CrossRefPubMedCentralPubMed
45.
Zurück zum Zitat Nakhlis F, Golshan M, Gilmore L, Gelman R, Iglehart J, Lawle ER et al. The incidence of adjacent synchronous invasive carcinoma and/or DCIS in patients with lobular neoplasia on core biopsy: results from a prospective multi-institutional registry (TBCRC 020), Presented at 68th annual Cancer Symposium, Society of Surgical Oncology, March 25–28, 2014, Houston, TX. Nakhlis F, Golshan M, Gilmore L, Gelman R, Iglehart J, Lawle ER et al. The incidence of adjacent synchronous invasive carcinoma and/or DCIS in patients with lobular neoplasia on core biopsy: results from a prospective multi-institutional registry (TBCRC 020), Presented at 68th annual Cancer Symposium, Society of Surgical Oncology, March 25–28, 2014, Houston, TX.
46.
Zurück zum Zitat Kohr JR et al. Risk of upgrade of atypical ductal hyperplasia after stereotactic breast biopsy: effects of number of foci and complete removal of calcifications. Radiology. 2010;255:723.CrossRefPubMed Kohr JR et al. Risk of upgrade of atypical ductal hyperplasia after stereotactic breast biopsy: effects of number of foci and complete removal of calcifications. Radiology. 2010;255:723.CrossRefPubMed
47.
Zurück zum Zitat Menes TS et al. Upgrade of high-risk breast lesions detected on mammography in the Breast Cancer Surveillance Consortium. Am J Surg. 2014;207:24.CrossRefPubMed Menes TS et al. Upgrade of high-risk breast lesions detected on mammography in the Breast Cancer Surveillance Consortium. Am J Surg. 2014;207:24.CrossRefPubMed
48.
Zurück zum Zitat Nguyen CV, Albarracin CT, Whitman GJ, Lopez A, Sneige N. Atypical ductal hyperplasia in directional vacuum-assisted biopsy of breast microcalcifications: considerations for surgical excision. Ann Surg Oncol. 2011;18:752.CrossRefPubMed Nguyen CV, Albarracin CT, Whitman GJ, Lopez A, Sneige N. Atypical ductal hyperplasia in directional vacuum-assisted biopsy of breast microcalcifications: considerations for surgical excision. Ann Surg Oncol. 2011;18:752.CrossRefPubMed
49.
Zurück zum Zitat Sneige N, Lim SC, Whitman GJ, Krishnamurthy S, Sahin AA, Smith TL, et al. Atypical ductal hyperplasia diagnosis by directional vacuum-assisted stereotactic biopsy of breast microcalcifications. Considerations for surgical excision. Am J Clin Pathol. 2003;119(2):248–53.CrossRefPubMed Sneige N, Lim SC, Whitman GJ, Krishnamurthy S, Sahin AA, Smith TL, et al. Atypical ductal hyperplasia diagnosis by directional vacuum-assisted stereotactic biopsy of breast microcalcifications. Considerations for surgical excision. Am J Clin Pathol. 2003;119(2):248–53.CrossRefPubMed
50.
Zurück zum Zitat Pandelidis S, Heiland D, Jones D, et al. Accuracy of 11-gauge vacuum-assisted core biopsy of mammographic breast lesions. Ann Surg Oncol. 2003;10(1):43–7.CrossRefPubMed Pandelidis S, Heiland D, Jones D, et al. Accuracy of 11-gauge vacuum-assisted core biopsy of mammographic breast lesions. Ann Surg Oncol. 2003;10(1):43–7.CrossRefPubMed
51.
Zurück zum Zitat Houssami N, Ciatto S, Ellis I, et al. Underestimation of malignancy of breast core-needle biopsy: concepts and precise overall and category-specific estimates. Cancer. 2007;109(3):487–95.CrossRefPubMed Houssami N, Ciatto S, Ellis I, et al. Underestimation of malignancy of breast core-needle biopsy: concepts and precise overall and category-specific estimates. Cancer. 2007;109(3):487–95.CrossRefPubMed
52.
Zurück zum Zitat Ganesan N, Bevers TB, Ying J, Coyne R, Lane D, Albarracin C, Bedrosian I. Risk of breast cancer in women observed after core biopsy diagnosis of atypical ductal hyperplasia. Presented at 67th annual Cancer Symposium, Society of Surgical Oncology, March 12–15, 2014, Phoenix, AZ. Ganesan N, Bevers TB, Ying J, Coyne R, Lane D, Albarracin C, Bedrosian I. Risk of breast cancer in women observed after core biopsy diagnosis of atypical ductal hyperplasia. Presented at 67th annual Cancer Symposium, Society of Surgical Oncology, March 12–15, 2014, Phoenix, AZ.
53.
Zurück zum Zitat Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer in white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879–86.CrossRefPubMed Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer in white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879–86.CrossRefPubMed
54.
Zurück zum Zitat Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23:1111–30.CrossRefPubMed Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23:1111–30.CrossRefPubMed
55.
Zurück zum Zitat Pankratz VS, Hartmann LC, Degnim AC, et al. Assessment of the accuracy of the Gail model in women with atypical hyperplasia. J Clin Oncol. 2008;26:5374–9.CrossRefPubMedCentralPubMed Pankratz VS, Hartmann LC, Degnim AC, et al. Assessment of the accuracy of the Gail model in women with atypical hyperplasia. J Clin Oncol. 2008;26:5374–9.CrossRefPubMedCentralPubMed
56.
Zurück zum Zitat Boughey JC, Hartmann LC, Anderson SS, et al. Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia. J Clin Oncol. 2010;28:3591–6.CrossRefPubMedCentralPubMed Boughey JC, Hartmann LC, Anderson SS, et al. Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia. J Clin Oncol. 2010;28:3591–6.CrossRefPubMedCentralPubMed
57.
Zurück zum Zitat Hartmann LC, Radisky DC, Frost MH, Santen RJ, Vierkant RA, Benetti LL, et al. Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. Cancer Prev Res (Phila). 2014;7(2):211–7. doi:10.1158/1940-6207.CAPR-13-0222.CrossRef Hartmann LC, Radisky DC, Frost MH, Santen RJ, Vierkant RA, Benetti LL, et al. Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. Cancer Prev Res (Phila). 2014;7(2):211–7. doi:10.​1158/​1940-6207.​CAPR-13-0222.CrossRef
58.
Zurück zum Zitat Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57(2):75–89.CrossRefPubMed Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57(2):75–89.CrossRefPubMed
59.
Zurück zum Zitat Berg WA, Blume JD, Cormack JB, et al. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA. 2008;299(18):2151–63.CrossRefPubMedCentralPubMed Berg WA, Blume JD, Cormack JB, et al. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA. 2008;299(18):2151–63.CrossRefPubMedCentralPubMed
60.
Zurück zum Zitat Kuhl CK, Schrading S, Leutner CC, Morakkabati-Spitz N, Wardelmann E, Fimmers R, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(33):8469–76. doi:10.1200/jco.2004.00.4960.CrossRef Kuhl CK, Schrading S, Leutner CC, Morakkabati-Spitz N, Wardelmann E, Fimmers R, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(33):8469–76. doi:10.​1200/​jco.​2004.​00.​4960.CrossRef
61.
Zurück zum Zitat Lehman CD, Isaacs C, Schnall MD, Pisano ED, Ascher SM, Weatherall PT, et al. Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. Radiology. 2007;244(2):381–8. doi:10.1148/radiol.2442060461.CrossRefPubMed Lehman CD, Isaacs C, Schnall MD, Pisano ED, Ascher SM, Weatherall PT, et al. Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. Radiology. 2007;244(2):381–8. doi:10.​1148/​radiol.​2442060461.CrossRefPubMed
62.
Zurück zum Zitat Sardanelli F, Podo F, D’Agnolo G, Verdecchia A, Santaquilani M, Musumeci R, et al. Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results. Radiology. 2007;242(3):698–715. doi:10.1148/radiol.2423051965.CrossRefPubMed Sardanelli F, Podo F, D’Agnolo G, Verdecchia A, Santaquilani M, Musumeci R, et al. Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results. Radiology. 2007;242(3):698–715. doi:10.​1148/​radiol.​2423051965.CrossRefPubMed
63.
Zurück zum Zitat Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004;292(11):1317–25. doi:10.1001/jama.292.11.1317.CrossRefPubMed Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004;292(11):1317–25. doi:10.​1001/​jama.​292.​11.​1317.CrossRefPubMed
64.•
Zurück zum Zitat Mainiero MB, Lourenco A, Mahoney MC, Newell MS, Bailey L, Barke LD, et al. ACR Appropriateness Criteria Breast Cancer Screening. J Am Coll Radiol. 2013;10(1):11–4. doi:10.1016/j.jacr.2012.09.036. This article provides a summary of the available literature regarding breast cancer screening, including a discussion of supplemental screening.CrossRefPubMed Mainiero MB, Lourenco A, Mahoney MC, Newell MS, Bailey L, Barke LD, et al. ACR Appropriateness Criteria Breast Cancer Screening. J Am Coll Radiol. 2013;10(1):11–4. doi:10.​1016/​j.​jacr.​2012.​09.​036. This article provides a summary of the available literature regarding breast cancer screening, including a discussion of supplemental screening.CrossRefPubMed
66.
Zurück zum Zitat Coopey SB, Mazzola E, Buckley JM, et al. The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. Breast Cancer Res Treat. 2012;136:627–33.CrossRefPubMed Coopey SB, Mazzola E, Buckley JM, et al. The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. Breast Cancer Res Treat. 2012;136:627–33.CrossRefPubMed
67.
Zurück zum Zitat Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998;90:1371–88.CrossRefPubMed Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998;90:1371–88.CrossRefPubMed
68.
Zurück zum Zitat Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:1652–62.CrossRefPubMed Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:1652–62.CrossRefPubMed
69.
Zurück zum Zitat Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA. 2006;295:2727–41.CrossRefPubMed Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA. 2006;295:2727–41.CrossRefPubMed
70.
Zurück zum Zitat Vogel VG, Costantino JP, Wickerham DL, et al. Update of the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res. 2010;3(6):696–706.CrossRef Vogel VG, Costantino JP, Wickerham DL, et al. Update of the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res. 2010;3(6):696–706.CrossRef
71.
Zurück zum Zitat Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomized placebo-controlled trial. Lancet. 2014;383(9922):1041–8.CrossRefPubMed Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomized placebo-controlled trial. Lancet. 2014;383(9922):1041–8.CrossRefPubMed
72.
Zurück zum Zitat Goss PE, Ingle JN, Alés-Martínez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364(25):2381–91.CrossRefPubMed Goss PE, Ingle JN, Alés-Martínez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364(25):2381–91.CrossRefPubMed
73.•
Zurück zum Zitat Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31(23):2942–62. In women at increased risk of breast cancer aged ≥35 years, risk reduction therapy should be offered to reduce the risk of ER-positive breast cancer.CrossRefPubMed Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31(23):2942–62. In women at increased risk of breast cancer aged ≥35 years, risk reduction therapy should be offered to reduce the risk of ER-positive breast cancer.CrossRefPubMed
74.•
Zurück zum Zitat National Comprehensive Cancer Network. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Breast Cancer Risk Reduction (Version 1.2014). Accessed http://www.nccn.org/. The NCCN website provides up-to-date guidelines on breast cancer risk reduction and evidence-based literature support of risk-reducing strategies among high-risk women. National Comprehensive Cancer Network. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Breast Cancer Risk Reduction (Version 1.2014). Accessed http://​www.​nccn.​org/​. The NCCN website provides up-to-date guidelines on breast cancer risk reduction and evidence-based literature support of risk-reducing strategies among high-risk women.
Metadaten
Titel
Current Multidisciplinary Management of High-Risk Breast Lesions
verfasst von
Therese B. Bevers
Isabelle Bedrosian
Lavinia P. Middleton
Marion E. Scoggins
Publikationsdatum
01.06.2015
Verlag
Springer US
Erschienen in
Current Breast Cancer Reports / Ausgabe 2/2015
Print ISSN: 1943-4588
Elektronische ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-015-0179-y

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.